Multi-latin squares

A multi-latin square of order $n$ and index $k$ is an $n\times n$ array of multisets, each of cardinality $k$, such that each symbol from a fixed set of size $n$ occurs $k$ times in each row and $k$ times in each column. A multi-latin square of index $k$ is also referred to as a $k$-latin square. A $1$-latin square is equivalent to a latin square, so a multi-latin square can be thought of as a generalization of a latin square. In this note we show that any partially filled-in $k$-latin square of order $m$ embeds in a $k$-latin square of order $n$, for each $n\geq 2m$, thus generalizing Evans' Theorem. Exploiting this result, we show that there exist non-separable $k$-latin squares of order $n$ for each $n\geq k+2$. We also show that for each $n\geq 1$, there exists some finite value $g(n)$ such that for all $k\geq g(n)$, every $k$-latin square of order $n$ is separable. We discuss the connection between $k$-latin squares and related combinatorial objects such as orthogonal arrays, latin parallelepipeds, semi-latin squares and $k$-latin trades. We also enumerate and classify $k$-latin squares of small orders.Comment: Final version as sent to journa

Updates after the Near-Earth Commissioning Phase of Italian Spring Accelerometer – ISA

AbstractISA (Italian Spring Accelerometer) is a high sensitivity accelerometer flying, as scientific payload, on-board one of the two spacecraft (the Mercury Planetary Orbiter) of BepiColombo, the first ESA mission to Mercury. The first commissioning phase (performed in the period November 2018 - August 2019) allowed to verify the functionality of the instrument itself as well as of the related data handling and archiving system. Moreover, the acceleration measurements gathered in this time frame allow to envisage the potentiality of such an instrument as a high-accuracy monitor of the spacecraft mechanical environment

Comparison of prasugrel and clopidogrel used as antiplatelet medication for endovascular treatment of unruptured intracranial aneurysms: A meta-analysis

BACKGROUND: Clopidogrel is routinely used to decrease ischemic complications during neurointerventional procedures. However, the efficacy may be limited by antiplatelet resistance. PURPOSE: Our aim was to analyze the efficacy of prasugrel compared with clopidogrel in the cerebrovascular field. DATA SOURCES: A systematic search of 2 large databases was performed for studies published from 2000 to 2018. STUDY SELECTION: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we included studies reporting treatment-related outcomes of patients undergoing neurointerventional procedures under prasugrel, and studies comparing prasugrel and clopidogrel. DATA ANALYSIS: Random-effects meta-analysis was used to pool the overall rate of complications, ischemic and hemorrhagic events, and influence of the dose of prasugrel. DATA SYNTHESIS: In the 7 included studies, 682 and 672 unruptured intracranial aneurysms were treated under prasugrel (cases) and clopidogrel (controls), respectively. Low-dose (20 mg/5 mg; loading and maintenance doses) prasugrel compared with the standard dose of clopidogrel (300 mg/75 mg) showed a significant reduction in the complication rate (OR 0.36; 95% CI, 0.17–74, P .006; I2 0%). Overall, the ischemic complication rate was significantly higher in the clopidogrel group (40/672 6%; 95% CI, 3%–13%; I2 83% versus 16/682 2%; 95% CI, 1%–5%; I2 73%; P .03). Low and high loading doses of prasugrel were associated with 0.6% (5/535; 95% CI, 0.1%–1.6%; I2 0%) and 9.3% (13/147; 95% CI, 0.2%–18%; I2 60%) intraperiprocedural hemorrhages, respectively (P .001), whereas low and high maintenance doses of prasugrel were associated with 0% (0/433) and 0.9% (2/249; 95% CI, 0.3%–2%; I2 0%) delayed hemorrhagic events, respectively (P .001). LIMITATIONS: Retrospective series and heterogeneous endovascular treatments were limitations. CONCLUSIONS: In our study, low-dose prasugrel compared with clopidogrel premedication was associated with an effective reduction of the ischemic events with an acceptable rate of hemorrhagic complications

The Galileo for science (G4S 2.0) project. Measurement of the gravitational redshift with the Galileo satellites DORESA and MILENA

The G4S 2.0 project represents an important opportunity to perform fundamental physics measurements with the two Galileo-FOC satellites DORESA and MILENA in elliptic orbits. In this paper, we discuss the possibility to improve the current constraints on local position invariance via a new measurement of the gravitational redshift, taking into account both a new model of the satellites and more in-depth considerations on non-gravitational perturbations

Treatment of Intracranial Aneurysms with Self-Expandable Braided Stents: A Systematic Review and Meta-Analysis

International audience; BACKGROUND:The safety and efficacy of treatment with self-expandable braided stents (LEO and LVIS) required further investigation.PURPOSE:Our aim was to analyze the outcomes after treatment with braided stents.DATA SOURCES:A systematic search of 3 databases was performed for studies published from 2006 to 2017.STUDY SELECTION:According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we included studies reporting patients treated with LEO or LVIS stents.DATA ANALYSIS:Random-effects meta-analysis was used to pool the following: aneurysm occlusion rate, complications, and neurologic outcomes.DATA SYNTHESIS:Thirty-five studies evaluating 1426 patients treated with braided stents were included in this meta-analysis. Successful stent delivery and complete aneurysm occlusion were 97% (1041/1095; 95% CI, 95%-98%) (I2 = 44%) and 88.3% (1097/1256; 95% CI, 85%-91%) (I2 = 72%), respectively. Overall, treatment-related complications were 7.4% (107/1317; 95% CI, 5%-9%) (I2 = 44%). Ischemic/thromboembolic events (48/1324 = 2.4%; 95% CI, 1.5%-3.4%) (I2 = 27%) and in-stent thrombosis (35/1324 = 1.5%; 95% CI, 0.6%-1.7%) (I2 = 0%) were the most common complications. Treatment-related morbidity was 1.5% (30/1324; 95% CI, 0.9%-2%) and was comparable between the LEO and LVIS groups. Complication rates between the anterior (29/322 = 8.8%; 95% CI, 3.4%-12%) (I2 = 41%) versus posterior circulation (10/84 = 10.5%; 95% CI, 4%-16%) (I2 = 0%) and distal (30/303 = 8%; 95% CI, 4.5%-12%) (I2 = 48%) versus proximal aneurysms (14/153 = 9%; 95% CI, 3%-13%) (I2 = 46%) were comparable (P > .05).LIMITATIONS:Limitations were selection and publication biases.CONCLUSIONS:In this analysis, treatment with the LEO and LVIS stents was relatively safe and effective. The most common complications were periprocedural thromboembolisms and in-stent thrombosis. The rate of complications was comparable among anterior and posterior circulation aneurysms, as well as for proximal and distally located lesions

Calibrating the IXPE Observatory from Ground to Space

The Imaging X-ray Polarimetry Explorer (IXPE) will be the next SMEX mission launched by NASA in 2021 in collaboration with the Italian Space Agency (ASI). IXPE will perform groundbreaking measurements of imaging polarization in X-rays for a number of different classes of sources with three identical telescopes, finally (re)opening a window in the high energy Universe after more than 40 years since the first pioneering results. The unprecedented sensitivity of IXPE to polarization poses peculiar requirements on the payload calibration, e.g. the use of polarized and completely unpolarized radiation, both on ground and in orbit, and can not rely on a systematic comparison with results obtained by previous observatories. In this paper, we will present the IXPE calibration plan, describing both calibrations which will be performed on the detectors at INAF-IAPS in Rome (Italy) and the calibration on the mirror and detector assemblies which will be carried out at Marshall Space Flight Center in Huntsville, Alabama. On orbit calibrations, performed with calibrations sources mounted on a filter wheel and placed in front of each detector when necessary, will be presented as well

Clinical and Economic Impact of Adopting Noninvasive Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population.

peer reviewed[en] OBJECTIVE: To evaluate the clinical and economic impact of adopting noninvasive prenatal testing (NIPT) using circulating cell-free DNA as a first-line screening method for trisomy 21, 18, and 13 in the general pregnancy population. METHODS: A decision-analytical model was developed to assess the impact of adopting NIPT as a primary screening test compared to conventional screening methods. The model takes the Belgium perspective and includes only the direct medical cost of screening, diagnosis, and procedure-related complications. NIPT costs are EUR 260. Clinical outcomes and the cost per trisomy detected were assessed. Sensitivity analysis measured the impact of NIPT false-positive rate (FPR) on modelled results. RESULTS: The cost per trisomy detected was EUR 63,016 for conventional screening versus EUR 66,633 for NIPT, with a difference of EUR 3,617. NIPT reduced unnecessary invasive tests by 94.8%, decreased procedure-related miscarriages by 90.8%, and increased trisomies detected by 29.1%. Increasing the FPR of NIPT (from < 0.01 to 1.0%) increased the average number of invasive procedures required to diagnose a trisomy from 2.2 to 4.5, respectively. CONCLUSION: NIPT first-line screening at a reasonable cost is cost-effective and provides better clinical outcomes. However, modelled results are dependent on the adoption of an NIPT with a low FPR

In-flight calibration system of imaging x-ray polarimetry explorer

The NASA/ASI Imaging X-ray Polarimetry Explorer, which will be launched in 2021, will be the first instrument to perform spatially resolved X-ray polarimetry on several astronomical sources in the 2-8 keV energy band. These measurements are made possible owing to the use of a gas pixel detector (GPD) at the focus of three X-ray telescopes. The GPD allows simultaneous measurements of the interaction point, energy, arrival time, and polarization angle of detected X-ray photons. The increase in sensitivity, achieved 40 years ago, for imaging and spectroscopy with the Einstein satellite will thus be extended to X-ray polarimetry for the first time. The characteristics of gas multiplication detectors are subject to changes over time. Because the GPD is a novel instrument, it is particularly important to verify its performance and stability during its mission lifetime. For this purpose, the spacecraft hosts a filter and calibration set (FCS), which includes both polarized and unpolarized calibration sources for performing in-flight calibration of the instruments. In this study, we present the design of the flight models of the FCS and the first measurements obtained using silicon drift detectors and CCD cameras, as well as those obtained in thermal vacuum with the flight units of the GPD. We show that the calibration sources successfully assess and verify the functionality of the GPD and validate its scientific results in orbit; this improves our knowledge of the behavior of these detectors in X-ray polarimetry

Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry: The EuroCTO (CASTLE) Score.

OBJECTIVES: The aim was to establish a contemporary scoring system to predict the outcome of chronic total occlusion coronary angioplasty. BACKGROUND: Interventional treatment of chronic total coronary occlusions (CTOs) is a developing subspecialty. Predictors of technical success or failure have been derived from datasets of modest size. A robust scoring tool could facilitate case selection and inform decision making. METHODS: The study analyzed data from the EuroCTO registry. This prospective database was set up in 2008 and includes >20,000 cases submitted by CTO expert operators (>50 cases/year). Derivation (n = 14,882) and validation (n = 5,745) datasets were created to develop a risk score for predicting technical failure. RESULTS: There were 14,882 patients in the derivation dataset (with 2,356 [15.5%] failures) and 5,745 in the validation dataset (with 703 [12.2%] failures). A total of 20.2% of cases were done retrogradely, and dissection re-entry was performed in 9.3% of cases. We identified 6 predictors of technical failure, collectively forming the CASTLE score (Coronary artery bypass graft history, Age (≥70 years), Stump anatomy [blunt or invisible], Tortuosity degree [severe or unseen], Length of occlusion [≥20 mm], and Extent of calcification [severe]). When each parameter was assigned a value of 1, technical failure was seen to increase from 8% with a CASTLE score of 0 to 1, to 35% with a score ≥4. The area under the curve (AUC) was similar in both the derivation (AUC: 0.66) and validation (AUC: 0.68) datasets. CONCLUSIONS: The EuroCTO (CASTLE) score is derived from the largest database of CTO cases to date and offers a useful tool for predicting procedural outcome

Mda-9/Syntenin Is Expressed in Uveal Melanoma and Correlates with Metastatic Progression

Uveal melanoma is an aggressive cancer that metastasizes to the liver in about half of the patients, with a high lethality rate. Identification of patients at high risk of metastases may provide indication for a frequent follow-up for early detection of metastases and treatment. The analysis of the gene expression profiles of primary human uveal melanomas showed high expression of SDCBP gene (encoding for syndecan-binding protein-1 or mda-9/syntenin), which appeared higher in patients with recurrence, whereas expression of syndecans was lower and unrelated to progression. Moreover, we found that high expression of SDCBP gene was related to metastatic progression in two additional independent datasets of uveal melanoma patients. More importantly, immunohistochemistry showed that high expression of mda-9/syntenin protein in primary tumors was significantly related to metastatic recurrence in our cohort of patients. Mda-9/syntenin expression was confirmed by RT-PCR, immunofluorescence and immunohistochemistry in cultured uveal melanoma cells or primary tumors. Interestingly, mda-9/syntenin showed both cytoplasmic and nuclear localization in cell lines and in a fraction of patients, suggesting its possible involvement in nuclear functions. A pseudo-metastatic model of uveal melanoma to the liver was developed in NOD/SCID/IL2Rγ null mice and the study of mda-9/syntenin expression in primary and metastatic lesions revealed higher mda-9/syntenin in metastases. The inhibition of SDCBP expression by siRNA impaired the ability of uveal melanoma cells to migrate in a wound–healing assay. Moreover, silencing of SDCBP in mda-9/syntenin-high uveal melanoma cells inhibited the hepatocyte growth factor (HGF)-triggered invasion of matrigel membranes and inhibited the activation of FAK, AKT and Src. Conversely syntenin overexpression in mda-9/syntenin-low uveal melanoma cells mediated opposite effects. These results suggest that mda-9/syntenin is involved in uveal melanoma progression and that it warrants further investigation as a candidate molecular marker of metastases and a potential therapeutic target